- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Stephen Wilcox
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Australian Government invests in new medicines for COVID-19
2 June 2020
The Australian Government will invest $3M in Walter and Eliza Hall Institute research programs that are developing new classes of medicines for COVID-19.
has announced new funding for COVID-19 research projects
led by Associate Professor Wai-Hong Tham (centre) and
Professor David Komander (right).
The funding from the Medical Research Future Fund (MRFF) will support two Institute research programs, part of a $66M investment by the Australian Government in research efforts to combat COVID-19. The grants were announced today by Australian Health Minister the Hon. Greg Hunt MP at the Walter and Eliza Hall Institute.
The two Institute programs are developing new medicines for COVID-19 and other coronaviruses, by leveraging the Institute’s established expertise in infectious disease research, protein biology, drug discovery, high-throughput screening and medicinal chemistry.
At a glance
- New funding from the Medical Research Future Fund (MRFF) will provide a boost to two research programs at the Institute that are developing new medicines for COVID-19.
- One program will target the virus’ protein machinery that helps it to reproduce and spread, while the other will develop ‘biologics’ medicines that block the virus from entering cells.
- The programs rely on Institute researchers’ expertise in drug discovery, infectious diseases and protein biology, and utilise key facilities including the National Drug Discovery Centre.
New medicines for COVID-19
The new funding from the MRFF is an important boost to the Walter and Eliza Hall Institute’s research efforts to tackle COVID-19. This includes programs that are developing better ways to diagnose COVID-19, as well as new preventative and treatment strategies.
COVID-19 is caused by the SARS-CoV-2 coronavirus – part of a family of viruses that include the causative agents of SARS and MERS. The Institute’s COVID-19 research is being undertaken both with the aim of combatting the current COVID-19 pandemic, as well as contributing to a new ‘tool kit’ of strategies that could be rapidly deployed to combat any future coronavirus outbreaks.
The MRFF grants will provide vital funding for two Institute research programs that are taking different approaches to develop new medicines for COVID-19.
Targeting a key viral protein
One program, VirDUB, is focussed on discovering drugs that block a coronavirus protein called PLpro. This protein, found in all coronaviruses, is essential for the virus to hijack human cells and disable their anti-viral defences.
Professor David Komander, who is leading VirDUB, said PLpro mediates a process called ‘deubiquitination’, that alters proteins in cells. “PLPro is very similar to human and viral ‘deubiquitinase’ (DUB) proteins that my team has studied for many years. We know DUBs are ideal targets for drug discovery. Here, we want to directly stop an essential viral DUB from functioning within cells to break the viral life cycle,” he said.
The new MRFF funding will accelerate VirDUB’s work towards new drugs that inhibit coronavirus PLpro. The program brings together researchers at the Institute with expertise in deubiquitination, structural biology, medicinal chemistry, drug discovery and virology, and accesses the infrastructure of the National Drug Discovery Centre, a facility based at the Walter and Eliza Hall Institute.
“Drugs that inhibit PLpro could potentially be used to treat people in early stages of COVID-19, as well as to protect people from infection. By targeting a viral system that is found in a range of coronaviruses, VirDUB may lead to new medicines that could be available to tackle potential future disease outbreaks caused by other coronaviruses,” Professor Komander said.
Developing ‘biologics’ medicines
The second program, led by Associate Professor Wai-Hong Tham, is developing new ‘biologics’ medicines to prevent or treat COVID-19. Biologics are medicines that mimic naturally occurring proteins such as antibodies – immune proteins that fight infection. Antibodies are already in clinical use for diseases such as cancer and inflammatory and autoimmune conditions. Associate Professor Tham said her program is searching for new biologics medicines that prevent the COVID-19 coronavirus, SARS-CoV-2, from binding to human lung cells – the first step in the virus infection cycle.
“Our consortium is searching for antibodies that block the interaction between the ‘spike’ protein on the surface of the SARS-CoV-2 virus and the ACE2 receptor on human lung cells. These two proteins form the ‘lock and key’ system through which SARS-CoV-2 invades cells. If we can block these proteins’ interactions, we stop the virus infecting a cell,” she said. “Biologics medicines for COVID-19 could be important tools for preventing infections as well as treating people in the early stages of the disease.”
The biologics research program brings together the expertise of Victorian and Australian academic and industry leaders in infectious diseases and antibody therapeutics, at the Walter and Eliza Hall Institute, the Peter Doherty Institute, CSL, Affinity Bio, CSIRO, Burnet Institute and Kirby Institute. The research has also been boosted by a $500,000 funding grant from the Victorian Government.
Building on scientific expertise
Walter and Eliza Hall Institute director Professor Doug Hilton AO said the Institute had responded rapidly to the COVID-19 pandemic, by applying a diverse range of research expertise built over many years.
“We are thrilled to receive funding from the MRFF for these two key programs within our COVID-19 research portfolio, in addition to the support already provided by MRFF for the COVID SHIELD clinical trial,” he said.
“The two newly funded Institute programs are extremely promising, and could provide important steps to better control COVID-19, as well as providing vital new weapons that could be deployed against potential future coronavirus disease outbreaks,” he said.
Professor Hilton said the MRFF is a valuable and innovative approach to funding medical research.
“I am thrilled to see how the MRFF has been used by the Australian Government to rapidly support urgently needed COVID-19 research. Traditional funding cycles in Australia take many months from application to the delivery of funds, and in the current pandemic, that is time we don’t have. We need relevant research given every chance to succeed, as rapidly as possible.
Media inquiries
M: +61 475 751 811
E: communityrelations@wehi.edu.au
Super Content:
The NDDC enables medical researchers to access ultra-high throughput screening, fast tracking scientific discoveries into new medicines.
Our researchers are working towards better approaches to diagnose, treat and prevent the spread of coronaviruses, both to address the current COVID-19 global outbreak as well as in preparedness for likely future coronaviral disease outbreaks.
The Australian Government has committed to $25 million in funding to enhance drug discovery capabilities at the Institute’s Drug Discovery Centre.
Want to hear about our latest discoveries? Subscribe to our supporter newsletter, Illuminate.
Answers to some frequently asked questions about COVID SHIELD, the clinical trial looking at hydroxychloroquine as a preventative therapy for COVID-19.
WEHI researchers are studying ‘nanobodies’ – tiny immune proteins made by alpacas – in a bid to understand whether they might be effective in blocking SARS-CoV-2, the virus that causes COVID-19.
WEHI researchers are using extremely small antibodies that occur naturally in alpacas – called nanobodies – to develop biologics that could prevent the COVID-19 coronavirus from binding to human cells – the first step in the virus infection cycle.
The COVID PROFILE study will use blood samples from people who have recovered from COVID-19, and their close contacts, to look in detail at how immunity to the disease develops, how long it lasts and what happens when immunity is lost.